Hyperpigmentation remains one of the most common and distressing dermatologic concerns encountered in clinical practice. Its multifactorial etiology, chronicity, and therapeutic complexity make it a persistent challenge for dermatologists worldwide. As patient demand for effective pigment-modulating therapies continues to rise, staying current with mechanistic insight and evidence-based interventions is essential.

Autoimmune dermatologic disorders present a distinct set of diagnostic and management challenges in dermatology. While histopathology and direct immunofluorescence remain cornerstones of diagnosis, serologic testing—detecting circulating autoantibodies or autoantigens—plays an increasingly central role in diagnosis, prognostication, disease monitoring, and guiding therapy.¹ This article offers an updated overview of serologic and autoimmune testing in dermatologic disease, summarizing current research and delineating key clinical pitfalls and challenges in practice. 

Skin biostimulation is a regenerative technique that restores skin quality by stimulating collagen and elastin production. Used to treat scars and stretch marks, biostimulatory injectables, such as calcium hydroxylapatite (CaHA), poly-L-lactic acid (PLLA), and platelet-rich plasma (PRP), enhance dermal remodeling and elasticity. Supported by emerging clinical evidence, these treatments offer long-term improvement in texture and tone. This FAQ provides evidence-based guidance for clinicians on current best practices in skin biostimulation. 

Seborrheic dermatitis (SD) is a chronic, relapsing inflammatory skin disorder characterized by erythematous, scaly lesions affecting areas rich in sebaceous glands, most commonly the scalp, face, and upper trunk. Driven by an abnormal immune response to Malassezia species, SD represents a spectrum from mild dandruff to severe facial or truncal involvement, often fluctuating with environmental and systemic factors, such as stress, weather changes, and immunosuppression. 

The eyes often reveal more than vision-related pathology; they can be key indicators of underlying dermatologic disease. Many cutaneous disorders, such as atopic dermatitis, rosacea, autoimmune blistering diseases, and lupus erythematosus, present with distinctive ocular signs that may precede, mirror, or complicate skin involvement. Early recognition of eyelid, conjunctival, and periocular manifestations is critical to preventing irreversible ocular surface damage, scarring, or vision loss.

Lasers have become essential tools in dermatology, delivering precise, effective treatments for acne scars, pigmentation, hair removal, and skin rejuvenation. 

With rapid advances in fractional, picosecond, and non-ablative technologies, clinicians must stay current on best practices and safety guidelines. This FAQ highlights the top trending questions about lasers in dermatology, offering concise, evidence-based insights to help dermatologists make informed clinical decisions. 

Hair loss is one of the most common reasons patients seek dermatologic care, with significant psychosocial impact. Advances in molecular biology and immunology have revealed that hair follicles are dynamic mini organs with immune, hormonal, and regenerative functions.¹ Recent studies highlight the role of inflammation, hormonal signaling, and immune privilege disruption in the pathogenesis of alopecia. This article reviews the biology of hair growth, major causes of hair loss, and US Food and Drug Administration (FDA)-approved treatments. 

Pruritus, or chronic itch, remains one of the most distressing and quality-of-life impairing symptoms in dermatology. Over the past decade, understanding of the neuroimmune mechanisms driving itch has advanced dramatically, leading to the emergence of biologics and small molecules that target its molecular pathways. This review summarizes current and investigational therapies for atopic dermatitis (AD), psoriasis, and chronic spontaneous urticaria (CSU)—3 major pruritic dermatoses—while addressing real-world challenges in dermatologic practice.